CASE REPORT article
Front. Oncol.
Sec. Hematologic Malignancies
Volume 15 - 2025 | doi: 10.3389/fonc.2025.1583932
This article is part of the Research TopicBCL-2 Family Inhibitors in Hematologic MalignanciesView all 9 articles
Simnotrelvir/Ritonavir are effective in shortening the course of prolonged SARS-CoV-2 infection during anti-CD20 maintenance therapy in patients with follicular lymphoma
Provisionally accepted
- Jishou University First Affiliated Hospital, Jishou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Patients with hematologic malignancy had the possibility of persistent infection with COVID-19, particularly those who received anti-CD20 monoclonal antibody therapy for lymphoma,regardless of vaccination status. We report two cases of follicular lymphoma (FL) infected with Omicron virus that could not be confirmed by routine SARS-CoV-2 tests during maintenance therapy with an anti-CD20 agent, obinutuzumab or rituximab. In addition to immunomodulatory drugs, both of them took Simnotrelvir/Ritonavir to effectively alleviate the symptoms. The aim is to highlight the complexity of SARS-CoV-2 infection and to discuss why it is easy to be infected with COVID-19 for a long time in this fragile patient population and the response to such patients with unexplained respiratory symptoms during maintenance therapy. Patients with hematologic malignancies treated with anti-CD20 agent are at considerable risk of a prolonged disease course and recurrence of COVID-19 [1,2] . Specialized prevention, diagnostic and therapeutic strategies should be developed for this group of patients.
Keywords: follicular lymphoma, COVID19, Anti-CD20, SARS-CoV-2, Infection, simnotrelvir/ritonavir
Received: 26 Feb 2025; Accepted: 24 Jul 2025.
Copyright: © 2025 Yang, Tu, Peng, Peng, Li and Song. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Kui Song, Jishou University First Affiliated Hospital, Jishou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.